Payment overview · 2025
General Payments
$4,960.36
208 reported records · 26 companies
Healthcare provider profile · identity verified
Michael Seth Miller, D.O.
Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine · INDIANAPOLIS, IN · NPI 1730122268
Verified facts
What the public records show
CMS Open Payments records show Michael Seth Miller, D.O. received $4,960.36 in general payments during 2025 across 208 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Austedo Xr, Auvelity, Azstarys, Belbuca, Caplyta, Fanapt, Invega Sustenna, Lybalvi, Ozempic, Qelbree, Rexulti, Secuado, Uzedy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Auvelity by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Belbuca by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Nucynta by this doctor in 2024.
Corium, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Azstarys as an associated drug or biological on 54930 records involving 15827 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Azstarys by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Rexulti by this doctor in 2024.
Noven Therapeutics, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Secuado as an associated drug or biological on 1988 records involving 1044 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Secuado by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Rexulti by this doctor in 2024.
Supernus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Qelbree as an associated drug or biological on 61278 records involving 18421 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Qelbree by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Austedo Xr by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Uzedy by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $940.48 | 19.0% | 49 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $569.09 | 11.5% | 31 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $498.57 | 10.1% | 18 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $494.50 | 10.0% | 17 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $374.79 | 7.6% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $296.49 | 6.0% | 7 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $264.99 | 5.3% | 12 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $230.25 | 4.6% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $209.46 | 4.2% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $165.98 | 3.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $156.04 | 3.1% | 9 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $139.54 | 2.8% | 8 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $131.28 | 2.6% | 6 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $102.86 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.89 | 1.5% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $70.11 | 1.4% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $49.88 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.93 | 0.6% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $28.48 | 0.6% | 1 | 2025 |
| HARTMANN USA, INC. | Unresolved — no canonical attribution shown | $25.59 | 0.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $24.29 | 0.5% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $18.47 | 0.4% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $18.36 | 0.4% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $15.89 | 0.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.61 | 0.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.54 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,843.20 | 205 |
| Education | $117.16 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $670.05 | 37 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $540.04 | 27 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $498.57 | 18 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $494.50 | 17 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $368.50 | 15 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $320.28 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $296.49 | 7 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $257.47 | 11 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $230.25 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $209.46 | 10 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $166.23 | 12 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $165.98 | 3 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $165.94 | 11 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $139.54 | 8 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $139.54 | 8 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $131.28 | 6 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $102.86 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.89 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $70.11 | 4 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $66.20 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $54.51 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $49.88 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| ZETUVIT PLUS 10X10 P10 Normalized: zetuvit plus 10x10 p10 |
Device | HARTMANN USA, INC. | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| Miro 3D Normalized: miro 3d |
Device | Reprise Biomedical, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $12.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 94 | exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 89 | exact normalized | Medicare Part D |
| Azstarys azstarys |
2025 | Azstarys | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Belbuca belbuca |
2025 | Belbuca | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 77 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 143 | exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 234 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| Qelbree qelbree |
2025 | Qelbree | 2024 | 57 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 164 | exact normalized | Medicare Part D |
| Secuado secuado |
2025 | Secuado | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UZEDY uzedy |
2025 | Uzedy | 2024 | 62 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 143 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
143 | 16 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
234 | 31 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Corium, LLC Exact reporting entity; no affiliate inference |
2025 | Azstarys open payments reported associated product |
CMS Open Payments — General Payments 54930 supporting records · 15827 recipient NPIs · example record 1185762907 |
Azstarys · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
143 | 20 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
164 | 23 |
| Noven Therapeutics, LLC Exact reporting entity; no affiliate inference |
2025 | Secuado open payments reported associated product |
CMS Open Payments — General Payments 1988 supporting records · 1044 recipient NPIs · example record 1240398301 |
Secuado · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
164 | 23 |
| Supernus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | Qelbree open payments reported associated product |
CMS Open Payments — General Payments 61278 supporting records · 18421 recipient NPIs · example record 1244861775 |
Qelbree · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | UZEDY open payments reported associated product |
CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226 |
Uzedy · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 757 | 92 |
| Risperidone | Risperidone | 717 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 712 | 68 |
| Sertraline Hcl | Sertraline Hcl | 668 | 67 |
| Buspirone Hcl | Buspirone Hcl | 666 | 88 |
| Clonazepam | Clonazepam | 542 | 56 |
| Benztropine Mesylate | Benztropine Mesylate | 510 | 57 |
| Divalproex Sodium | Divalproex Sodium | 501 | 48 |
| Aripiprazole | Aripiprazole | 476 | 60 |
| Olanzapine | Olanzapine | 466 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 450 | 47 |
| Carvedilol | Carvedilol | 440 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 430 | 54 |
| Metformin Hcl | Metformin Hcl | 382 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 50 |
| Clozapine | Clozapine | 363 | 24 |
| Lorazepam | Lorazepam | 361 | 44 |
| Ezetimibe | Ezetimibe | 354 | 39 |
| Divalproex Sodium Er | Divalproex Sodium | 345 | 36 |
| Omeprazole | Omeprazole | 342 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 36 |
| Lisinopril | Lisinopril | 327 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 324 | 34 |
| Clonidine Hcl | Clonidine Hcl | 285 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 284 | 64 |
| Lamotrigine | Lamotrigine | 282 | 35 |
| Oxcarbazepine | Oxcarbazepine | 270 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 31 |
| Famotidine | Famotidine | 249 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 34 |
| Gabapentin | Gabapentin | 240 | 32 |
| Mirtazapine | Mirtazapine | 239 | 36 |
| Lybalvi | Olanzapine/Samidorphan Malate | 234 | 31 |
| Naltrexone Hcl | Naltrexone Hcl | 234 | 27 |
| Prazosin Hcl | Prazosin Hcl | 218 | 23 |
| Simvastatin | Simvastatin | 208 | 23 |
| Propranolol Hcl | Propranolol Hcl | 201 | 22 |
| Topiramate | Topiramate | 197 | 23 |
| Paliperidone Er | Paliperidone | 193 | 21 |
| Lurasidone Hcl | Lurasidone Hcl | 188 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 30 |
| Ziprasidone Hcl | Ziprasidone Hcl | 178 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 176 | 19 |
| Donepezil Hcl | Donepezil Hcl | 170 | 20 |
| Rexulti | Brexpiprazole | 164 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 18 |
| Losartan Potassium | Losartan Potassium | 149 | 20 |
| Alprazolam | Alprazolam | 146 | 16 |
| Invega Sustenna | Paliperidone Palmitate | 143 | 20 |
| Vraylar | Cariprazine Hcl | 143 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 17 |
| Lithium Carbonate | Lithium Carbonate | 140 | 14 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 135 | 21 |
| Furosemide | Furosemide | 133 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 132 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 17 |
| Bupropion Xl | Bupropion Hcl | 131 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 44 |
| Quviviq | Daridorexant Hcl | 128 | 19 |
| Guanfacine Hcl Er | Guanfacine Hcl | 126 | 16 |
| Ramelteon | Ramelteon | 126 | 20 |
| Levetiracetam | Levetiracetam | 123 | 15 |
| Montelukast Sodium | Montelukast Sodium | 119 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 115 | 35 |
| Carbamazepine | Carbamazepine | 114 | 11 |
| Glipizide | Glipizide | 114 | 12 |
| Potassium Chloride | Potassium Chloride | 112 | 15 |
| Diazepam | Diazepam | 110 | 24 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 108 | 23 |
| Haloperidol | Haloperidol | 104 | 21 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 103 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | suppressed |
| Austedo Xr | Deutetrabenazine | 94 | 20 |
| Desmopressin Acetate | Desmopressin Acetate | 94 | suppressed |
| Fenofibrate | Fenofibrate | 93 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 92 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 11 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 89 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 88 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | suppressed |
| Ibuprofen | Ibuprofen | 82 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 81 | suppressed |
| Ozempic | Semaglutide | 80 | 14 |
| Meloxicam | Meloxicam | 79 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 78 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 78 | suppressed |
| Caplyta | Lumateperone Tosylate | 77 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 12 |
| Atomoxetine Hcl | Atomoxetine Hcl | 74 | suppressed |
| Lacosamide | Lacosamide | 68 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 32 |
| Doxepin Hcl | Doxepin Hcl | 67 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 67 | 18 |
| Fanapt | Iloperidone | 66 | suppressed |
| Hydrocortisone | Hydrocortisone | 66 | 16 |
| Atenolol | Atenolol | 65 | suppressed |
| Memantine Hcl | Memantine Hcl | 65 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | suppressed |
| Uzedy | Risperidone | 62 | 14 |
| Alendronate Sodium | Alendronate Sodium | 60 | suppressed |
| Baclofen | Baclofen | 58 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | suppressed |
| Qelbree | Viloxazine Hcl | 57 | 12 |
| Austedo | Deutetrabenazine | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 24 |
| Glipizide Er | Glipizide | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 52 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 52 | suppressed |
| Belbuca | Buprenorphine Hcl | 50 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 13 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Lactulose | Lactulose | 49 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 49 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 48 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 48 | suppressed |
| Perseris | Risperidone | 48 | 13 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 47 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 46 | suppressed |
| Celecoxib | Celecoxib | 46 | suppressed |
| Pregabalin | Pregabalin | 45 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 14 |
| Eliquis | Apixaban | 44 | suppressed |
| Belsomra | Suvorexant | 41 | suppressed |
| Nucynta | Tapentadol Hcl | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 39 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 17 |
| Dayvigo | Lemborexant | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Amantadine | Amantadine Hcl | 36 | suppressed |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Nucynta Er | Tapentadol Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Scopolamine | Scopolamine | 35 | suppressed |
| Zonisamide | Zonisamide | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 34 | suppressed |
| Carbamazepine Er | Carbamazepine | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 18 |
| Abilify Maintena | Aripiprazole | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 29 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | suppressed |
| Nystop | Nystatin | 26 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Buprenorphine | Buprenorphine | 25 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Ursodiol | Ursodiol | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Levocarnitine | Levocarnitine | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Niacin Er | Niacin | 24 | suppressed |
| Olanzapine Odt | Olanzapine | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 22 | suppressed |
| Savella | Milnacipran Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Secuado | Asenapine | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Admelog Solostar | Insulin Lispro | 19 | suppressed |
| Aristada | Aripiprazole Lauroxil | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Azstarys | Serdexmethylphen/Dexmethylphen | 18 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 17 | suppressed |
| Lamotrigine Er | Lamotrigine | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 16 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Tri-Lo-Mili | Norgestimate-Ethinyl Estradiol | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Gralise | Gabapentin | 14 | suppressed |
| Horizant | Gabapentin Enacarbil | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Risperidone Odt | Risperidone | 14 | suppressed |
| Symproic | Naldemedine Tosylate | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Igalmi | Dexmedetomidine Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Norethindrone | Norethindrone | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Fetzima | Levomilnacipran Hcl | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,960.36 · 208 records | Teva Pharmaceuticals USA, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, Belbuca, CAPLYTA, COBENFY, EPIDIOLEX, ERZOFRI EXTENDED-RELEASE, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, JOURNAVX, LYBALVI, MOUNJARO, Miro 3D, Ozempic, QUTENZA, Qelbree, REXULTI, REZDIFFRA, Rybelsus, SPRAVATO, SUBLOCADE, Secuado, UZEDY, VRAYLAR, WAKIX, Wegovy, Xelstrym, ZEPBOUND, ZETUVIT PLUS 10X10 P10 | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error